1. Cytokinetics, Incorporated (NASDAQ:CYTK)
Stock Upside Potential: 38.85%
Number of Hedge Fund Holders: 65
Cytokinetics (NASDAQ:CYTK) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 4, B. Riley initiated coverage of Cytokinetics (NASDAQ:CYTK) with a Buy rating and a $108 price target. The positive stance underscores the research firm’s confidence about the company’s ability to capture market share in the cardiac myosin inhibitor space.
The company has already started flexing its muscles in the space with Myqorzo, its candidate drug approved by the US Food and Drug Administration for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). According to B.Riley, the company’s competitive edge stems from its candidate drug’s “materially streamlined REMS” compared to Bristol Myers Squibb’s CAMZYOS.
Launched at the start of the year, Myqorzo has zero drug-drug interaction pharmacy recalls , more flexible echo windows, and faster dose stabilization. While there are about 11,000 active CAMZYOS patients, higher attrition rates suggest a sizable 5K churned patients that Cytokinetics can target with its drug.
On January 28, Barclays initiated coverage of the stock with an Overweight rating and an $87 price target. The investment bank has touted the company’s prospects following the launch of Myqorzo, a differentiated label that reduces the need for echocardiogram monitoring.
Cytokinetics, Incorporated (NASDAQ:CYTK) is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle-directed medicines to treat serious diseases, particularly those affecting cardiovascular and neuromuscular function. Founded in 1997, the company specializes in muscle biology to develop small-molecule compounds that act as either activators or inhibitors to improve muscle function.
While we acknowledge the potential of CYTK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CYTK and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Stocks to Buy and Hold for the Next 6 Months and 11 Best High Return Penny Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
